Ebola Outbreak in DRC and Uganda Intensifies: WHO Reports 534 Confirmed Cases

Ebola Outbreak in DRC and Uganda Intensifies: WHO Reports Expanding Crisis

The ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda continues to escalate, with the World Health Organization (WHO) reporting 550 confirmed cases and 101 deaths in the DRC as of June 9, 2026. The outbreak, caused by the Bundibugyo virus species — one of the six known species of Ebolavirus — has emerged as a significant public health emergency in Central Africa.

The Ituri province of northeastern DRC remains the epicenter of the outbreak, accounting for 518 of the 550 confirmed cases. In neighboring Uganda, 19 cases have been confirmed, including 2 deaths, marking the first cross-border transmission of this outbreak. The situation has prompted enhanced public health measures across the region and raised international concern.

Current Situation: A Growing Public Health Emergency

The WHO’s latest situation report, released on June 9, paints a concerning picture of the outbreak’s trajectory:

• DRC total: 550 confirmed cases, 101 deaths (case fatality rate: 18.4%)
• Ituri province: 518 cases — the worst-affected area with sustained community transmission
• Other DRC provinces: 32 cases reported in North Kivu and Tshopo provinces
• Uganda: 19 confirmed cases including 2 deaths, primarily in Kasese district near the DRC border
• Healthcare workers: 27 infections among healthcare workers, reflecting massive gaps in infection prevention and control

The Bundibugyo Virus: A Unique Challenge

Unlike the more well-known Zaire ebolavirus (which caused the devastating 2014-2016 West Africa outbreak and the 2018-2020 Kivu outbreak), the Bundibugyo virus presents unique challenges for outbreak response:

• No approved vaccine: While vaccines exist for the Zaire species (rVSV-ZEBOV, approved by WHO and FDA), there is currently no licensed vaccine targeting Bundibugyo virus
• No approved treatment: No antiviral therapies have been specifically approved for Bundibugyo infection, though supportive care and investigational treatments are being deployed
• Distinct clinical profile: Bundibugyo has a lower case fatality rate (typically 25-40%) compared to Zaire (50-90%), but the lack of approved countermeasures poses significant response challenges
• High transmissibility: Bundibugyo spreads through the same routes as other Ebola species — direct contact with blood, body fluids, and contaminated surfaces

“Bundibugyo virus is a formidable pathogen,” explains Dr. Amara Diallo, an Ebola specialist at the WHO’s Health Emergencies Programme. “The absence of a licensed vaccine means our control strategies must rely entirely on traditional public health measures: case detection, contact tracing, safe burial practices, and community engagement.”

International Response and Travel Measures

The international community has mobilized in response to the expanding outbreak:

• CDC enhanced travel screening: The U.S. Centers for Disease Control and Prevention has implemented enhanced entry screening at major international airports for travelers arriving from affected regions
• American patient airlifted to Germany: A U.S. national infected with Bundibugyo virus in the DRC has been medically evacuated to a specialized high-containment treatment facility in Germany, underscoring the international dimensions of the outbreak
• WHO risk assessment: The WHO has assessed the risk as very high at the national level in the DRC, high for neighboring countries (Uganda, Rwanda, Burundi, South Sudan), and low globally
• MSF and NGO deployment: Médecins Sans Frontières (MSF) and other humanitarian organizations have deployed outbreak response teams to affected areas
• Ring vaccination trials: Investigational vaccines for Bundibugyo are being considered for deployment under compassionate use protocols and clinical trial frameworks

Clinical Presentation and Management

Health professionals should be familiar with the clinical presentation of Bundibugyo virus disease:

• Incubation period: 2-21 days (typically 8-12 days)
• Initial symptoms: Sudden onset of fever, fatigue, muscle pain, headache, and sore throat
• Progressive symptoms: Vomiting, diarrhea, rash, impaired kidney and liver function
• Hemorrhagic phase: Internal and external bleeding occurs in approximately 30-50% of cases
• Supportive care: Intravenous fluids, electrolyte management, oxygen therapy, and treatment of co-infections remain the cornerstone of clinical management

The lower case fatality rate of Bundibugyo compared to Zaire ebolavirus may reflect both inherent differences in viral pathogenicity and improved supportive care protocols developed after the 2014-2016 and 2018-2020 outbreaks.

Challenges in Outbreak Response

Several factors are complicating the response to this outbreak:

• Security concerns: Ituri province has experienced ongoing armed conflict, impeding access for response teams and creating population displacement that accelerates disease spread
• Community mistrust: Historical tensions between communities and health authorities, exacerbated by misinformation, have led to some resistance to public health measures
• Cross-border movement: The porous border between DRC and Uganda facilitates daily movement of people, making containment across the border extremely challenging
• Limited countermeasures: Without an approved vaccine or treatment for Bundibugyo, traditional outbreak control tools must work harder and faster

Frequently Asked Questions

What is Bundibugyo virus?

Bundibugyo virus is one of six known species of Ebolavirus, named after the Bundibugyo district in Uganda where it was first identified during a 2007 outbreak. It causes Ebola virus disease with typical symptoms including fever, vomiting, diarrhea, and in some cases hemorrhagic manifestations. Its case fatality rate (25-40%) is lower than the Zaire species but it remains a significant public health threat.

Is there a vaccine for Bundibugyo virus?

No. Currently licensed Ebola vaccines (such as rVSV-ZEBOV, branded as Ervebo) are specific to Zaire ebolavirus and are not approved for Bundibugyo. Investigational vaccines are being developed, and clinical trials may be deployed in the current outbreak under compassionate use protocols, but no licensed vaccine is currently available.

Should travelers avoid affected areas?

The WHO advises against any travel restrictions to DRC or Uganda at this time. However, travelers to affected areas should practice standard precautions: avoid contact with symptomatic individuals, avoid contact with blood and body fluids, avoid handling of bushmeat, and practice rigorous hand hygiene. Health professionals traveling to or returning from affected areas should monitor for symptoms for 21 days after potential exposure.

How does Ebola spread?

Ebola is spread through direct contact with blood, body fluids (urine, saliva, sweat, feces, vomit, breast milk, semen), or contaminated objects (needles, bedding) of a person who is sick with or has died from Ebola. It is not airborne. The virus can also be transmitted through contact with infected animals, particularly fruit bats, primates, and forest antelopes.

What is the treatment for Bundibugyo virus disease?

There is no specific approved antiviral treatment for Bundibugyo virus disease. Management consists of supportive care: intravenous fluids to prevent dehydration, electrolyte monitoring and replacement, oxygen therapy, blood pressure support, and treatment of any co-infections. Investigational therapies may be available through clinical trials or compassionate use protocols.

Is the global risk high?

The WHO assesses the global risk as low. The outbreak remains geographically concentrated in northeastern DRC and adjacent areas of Uganda. While the international evacuation of an American patient to Germany demonstrates global interconnectedness, established public health systems in most countries are fully capable of detecting, isolating, and managing imported cases. The greatest risk is to the affected regions and their immediate neighbors.

What should health professionals outside Africa know?

Health professionals worldwide should maintain awareness of the outbreak and include Ebola in their differential diagnosis for patients with fever and travel history to affected areas in the 21 days before symptom onset. Suspected cases should be immediately isolated, and local health authorities should be contacted for guidance on diagnostic testing and case management protocols.